Background:

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease.

Applications:

WB

Name of antibody:

SNCA(Ab-125)

Immunogen:

Synthesized non-phosphopeptide derived from human Synuclein-α around the phosphorylation site of tyrosine 125 (E-A-Y(p)-E-M).

Full name:

synuclein, alpha (non A4 component of amyloid precursor)

Synonyms：

PD1; NACP; PARK1; PARK4

SwissProt:

P37840

WB Predicted band size:

14 kDa

WB Positive control:

Rat brain and mouse brain tissue lysates

WB Recommended dilution:

500-3000